Skip to content
stockresearch.app
WST/History

West Pharmaceutical Services (WST) valuation history

Historically high

As of

WST's EV/EBITDA of 32.3x is higher than 99% of its available weekly readings from the last five years.

Compared with readings since .

EV/EBITDA weekly history18.7×23.9×29.2×34.5×Shading: 5-year middle halfMedian 25.1×32.3×202120232025
Share EV/EBITDA history
Preview embed

Chart by stockresearch.app. Reuse with credit under CC BY 4.0.

EV/EBITDA at year-end

Last weekly reading of each completed year. Rank runs from lowest (0%) to highest (100%) within the five years available on that date.

WST year-end valuation history
Reading dateEV/EBITDA5-year rank
26.1×86%
UnavailableShort history
UnavailableShort history
UnavailableShort history
UnavailableShort history
UnavailableShort history
UnavailableShort history
UnavailableShort history
UnavailableShort history
UnavailableShort history

Loading related research…

About this history

What is WST's current EV/EBITDA?
WST's EV/EBITDA of 32.3x is higher than 99% of its available weekly readings from the last five years.
What is WST's five-year median EV/EBITDA?
The median, or middle weekly reading, is 25.1× over the last five years. Available history contains 533 weekly observations from Aug 8, 2016 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?
No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.

Source: SEC company filings and weekly market prices. Multiples use the previous twelve months of financial results. Updated .

Read the valuation methodology